The Patent Cliff Returns: Can Big Pharma Innovate Fast Enough to Stay on Top?
For decades, blockbuster drugs have fueled the pharmaceutical industry’s golden age. But as the 2020s unfold, a familiar threat is resurfacing with unprecedented intensity: the Loss of Exclusivity (LOE). With patents on multibillion-dollar therapies nearing expiry, pharma giants are once again bracing for revenue shocks. Yet this time, the stakes are higher—and the playbooks are different. From bold R and D bets to surgical cost-cutting and smarter lifecycle management, the next 5 years will separate the truly future-ready players from the rest. Here is how three of the biggest names, Mer...
